National Cancer Institute (NCI) researchers are conducting a study of patients with ependymoma. Ependymomas are rare cancerous tumors that grow in the central nervous system. This study will test if the drug marizomib slows or stops the spread of cancer cells in the brain or spine. Results from this research study may help doctors to control these tumor types.
What the study involves:
• Physical and neurological examination
• EKG to evaluate the heart
• Patient questionnaire about health and symptoms
• MRIs and neurological function tests
• Study of tumor tissue from prior surgeries
• Your samples used for a health evaluation
• Receive drug marizomib for up to 24 cycles. Each cycle is four weeks.
You can participate if you:
• Are age 18 or older
• Are diagnosed with an ependymoma that has returned
• Have been treated with standard therapies
• Are not pregnant or breastfeeding
You can participate in this study by visiting the NIH for a clinical assessment.
The NIH Clinical Center, America’s Research Hospital located in Bethesda, MD
Metro red line (Medical Center stop)
For more information:
NIH Clinical Center Office of Patient Recruitment show contact info
For those who are Deaf, Hard-of-Hearing, or Speech Impaired show contact info
Se habla español
Refer to NIH Study: 19-C-0011
do NOT contact me with unsolicited services or offers